Page last updated: 2024-11-06

n-acetyl-4-benzoquinoneimine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetyl-4-benzoquinoneimine (NABQI) is a reactive metabolite of acetaminophen (paracetamol) that is formed in the liver by cytochrome P450 enzymes. It is a highly reactive electrophile that can bind to and damage cellular proteins, including those in the liver. This compound has been implicated in the hepatotoxicity of acetaminophen overdose. The formation of NABQI is believed to be a key step in the pathogenesis of acetaminophen-induced liver injury. NABQI reacts with glutathione, a major detoxification agent in the liver, to form a glutathione conjugate. This reaction is thought to be a major protective mechanism against acetaminophen-induced liver injury. NABQI has also been shown to inhibit mitochondrial respiration and to induce oxidative stress. These effects may contribute to the hepatotoxicity of acetaminophen. The formation and detoxification of NABQI are complex processes that are influenced by several factors, including genetic factors, environmental factors, and the presence of other drugs or chemicals. NABQI is an important target for research aimed at developing new strategies to prevent and treat acetaminophen-induced liver injury.'

N-acetyl-4-benzoquinoneimine: reactive arylating intermediate from acetaminophen & N-hydroxyacetaminophen; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID39763
CHEMBL ID33232
CHEBI ID29132
SCHEMBL ID354378
MeSH IDM0091607

Synonyms (38)

Synonym
n-acetyl-p-quinonimine
acetamide, n-(4-oxo-2,5-cyclohexadien-1-ylidene)-
n-(4-oxo-2,5-cyclohexadienylidene)acetamide
brn 2435621
2,5-cyclohexadien-1-one, 4-acetylimino-
n-(4-oxo-2,5-cyclohexadien-1-ylidene)acetamide
n-acetyl-p-benzoquinone
ccris 5789
n-acetyl-4-benzoquinoneimine
acetimidoquinone
50700-49-7
n-acetyl-1,4-benzoquinone imine
n-acetylbenzoquinoneimine
n-acetyl-p-benzoquinone imine
n-(4-oxocyclohexa-2,5-dien-1-ylidene)acetamide
4-acetylimino-2,5-cyclohexadien-1-one
napqi
CHEBI:29132 ,
n-acetyl-4-benzoquinone imine
CHEMBL33232 ,
1,4-benzodiazepin-3-one
unii-g6s9bn13ti
g6s9bn13ti ,
FT-0629797
n-(4-oxo-1-cyclohexa-2,5-dienylidene)acetamide
gtpl6299
n-acetyl-p-benzo-quinoneimine
n-acetyl-p-quinoneimine
acetimidoquinone [mi]
SCHEMBL354378
mfcd00078909
DTXSID20198756
4-(acetylimino)-2,5-cyclohexadien-1-one
Q6952342
n-(4-oxocyclohexa-2,5-dienylidene)acetamide
MS-22843
bdbm50458544
F87474

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"1 The ability of iloprost (ZK36374) to protect hamster isolated hepatocytes from the toxic effects of paracetamol and its reactive metabolite N-acetyl-p-benzoquinoneimine (NABQI) was investigated."( Cytoprotection by iloprost against paracetamol-induced toxicity in hamster isolated hepatocytes.
Boobis, AR; Davies, DS; Fawthrop, DJ; Nasseri-Sina, P; Wilson, J, 1992
)
0.28
" This suggests that DEDC acts as a trap for the toxic quinoneimines, thus preventing alkylation of essential macromolecules."( Molecular mechanism for prevention of N-acetyl-p-benzoquinoneimine cytotoxicity by the permeable thiol drugs diethyldithiocarbamate and dithiothreitol.
Lauriault, VV; O'Brien, PJ, 1991
)
0.28
" N-Acetyl-m-aminophenol (AMAP) was approximately 10-fold less toxic than APAP, despite the fact that it bound covalently to a greater extent to hepatocyte macromolecules."( Comparative cytotoxic effects of acetaminophen (N-acetyl-p-aminophenol), a non-hepatotoxic regioisomer acetyl-m-aminophenol and their postulated reactive hydroquinone and quinone metabolites in monolayer cultures of mouse hepatocytes.
Bjørge, C; Holme, JA; Hongslo, JK; Nelson, SD, 1991
)
0.28
" Dicumarol was toxic to cultured non-induced rat hepatocytes and produced little or no increase in quinoneimine toxicity."( Quinoneimines as substrates for quinone reductase (NAD(P)H: (quinone-acceptor)oxidoreductase) and the effect of dicumarol on their cytotoxicity.
Hodnett, EM; Melder, DC; Powis, G; Santone, KS; See, KL, 1987
)
0.27
" However, they also increased the susceptibility of hepatocytes to paracetamol toxicity, indicating that a component of paracetamol's toxic effect involves formation of species that are detoxified by the GSH-Px/GSSG-Rd enzymes."( A role for the glutathione peroxidase/reductase enzyme system in the protection from paracetamol toxicity in isolated mouse hepatocytes.
Adamson, GM; Harman, AW, 1989
)
0.28
"The effects of acetaminophen and its major toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI), have been investigated in hepatocytes isolated from 3-methylcholanthrene-pretreated and -untreated rats, respectively."( The toxicity of acetaminophen and N-acetyl-p-benzoquinone imine in isolated hepatocytes is associated with thiol depletion and increased cytosolic Ca2+.
Moldéus, P; Moore, G; Moore, M; Nelson, S; Orrenius, S; Thor, H, 1985
)
0.27
"N-acetyl-p-benzoquinone imine (NAPQI), a reactive metabolite of acetaminophen, has previously been shown to be toxic to hepatocytes freshly isolated from rat liver [Mol."( Comparative cytotoxic effects of N-acetyl-p-benzoquinone imine and two dimethylated analogues.
Cotgreave, IA; Harvison, PJ; Moldéus, P; Nelson, SD; Porubek, DJ; Rundgren, M, 1988
)
0.27
"The cytotoxicity of paracetamol and of its putative toxic metabolite, N-acetyl-p-benzo-quinoneimine (NABQI) have been investigated in hepatocytes from hamster, mouse, rat and human liver."( Species differences in the hepatotoxicity of paracetamol are due to differences in the rate of conversion to its cytotoxic metabolite.
Boobis, AR; Davies, DS; Seddon, CE; Tee, LB, 1987
)
0.27
" Species differences in sensitivity to paracetamol toxicity were shown to be due to differences in the rate of oxidation of the drug to its toxic metabolite."( Freshly isolated hepatocytes as a model for studying the toxicity of paracetamol.
Boobis, AR; Davies, DS; Hampden, CE; Tee, LB,
)
0.13
" In contrast, no toxic effects of pHAA (less than or equal to 20 mM) could be demonstrated."( Cytotoxic effects of N-acetyl-p-benzoquinone imine, a common arylating intermediate of paracetamol and N-hydroxyparacetamol.
Dahlin, DC; Dybing, E; Holme, JA; Nelson, SD, 1984
)
0.27
" Hepa 1c1c-9 cells were exposed to varying concentrations of several reactive metabolites implicated in adverse drug reactions and the toxicity of the compounds assessed using applied fluorescence technology."( A comparative study of the toxicity of chemically reactive xenobiotics towards adherent cell cultures: selective attenuation of menadione toxicity by buthionine sulphoximine pretreatment.
Leeder, JS; Riley, RJ; Spielberg, SP, 1993
)
0.29
" When administered 1 hour prior to, immediately after, or 20 minutes after a toxic dose of APAP, DASO2 at a dose of 25 mg/kg completely protected mice from development of hepatotoxicity, as indicated by liver histopathology and serum lactate dehydrogenase levels."( Protective effect of diallyl sulfone against acetaminophen-induced hepatotoxicity in mice.
Lee, MJ; Lin, MC; Patten, C; Reuhl, KR; Wang, EJ; Xiao, F; Yang, CS, 1996
)
0.29
" Incubation of the cells with CP (2 mM and 10 mM) drastically attenuated the GSH and cysteine depletion caused by toxic concentrations of paracetamol (1 mM and 5 mM)."( 2-Methyl-thiazolidine-2,4-dicarboxylic acid protects against paracetamol induced toxicity in human liver derived HepG2 cells.
Rommelspacher, H; Włodek, L, 1997
)
0.3
"Acetaminophen toxicity in hepatocytes is attributed to generation of the toxic metabolite N-acetyl-p-benzoquinoneimine, leading to depletion of intracellular glutathione, alteration of redox potential and ultimately, cellular necrosis."( Resistance of three immortalized human hepatocyte cell lines to acetaminophen and N-acetyl-p-benzoquinoneimine toxicity.
Edwards, RJ; Hodgson, HJ; McCloskey, P; Roberts, E; Selden, C; Tootle, R, 1999
)
0.3
"We demonstrated that HH25, HH29 and HHY41 are resistant to the toxic effects of acetaminophen under conditions that induce cytotoxicity in rat primary hepatocytes, as indicated by maintenance of glutathione levels and basal LDH release."( Resistance of three immortalized human hepatocyte cell lines to acetaminophen and N-acetyl-p-benzoquinoneimine toxicity.
Edwards, RJ; Hodgson, HJ; McCloskey, P; Roberts, E; Selden, C; Tootle, R, 1999
)
0.3
" This toxic reaction is associated with metabolic activation by the P450 system to form a quinoneimine metabolite, N-acetyl-p-benzoquinoneimine (NAPQI), which covalently binds to proteins and other macromolecules to cause cellular damage."( Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi.
Henderson, CJ; Kitteringham, N; Otto, D; Park, BK; Powell, H; Wolf, CR, 2000
)
0.31
" These results suggest an innovative therapeutic approach for treating the adverse effects of acetaminophen and potentially other hepatotoxic agents."( Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR.
Chua, SS; Huang, W; Moore, DD; Wei, P; Zhang, J, 2002
)
0.31
" We demonstrate that this non-negative area estimates the cellular burden of toxic adducts formed following overdose."( A new predictor of toxicity following acetaminophen overdose based on pretreatment exposure.
Good, AM; Johnson, DW; Juurlink, DN; Sivilotti, ML; Yarema, MC, 2005
)
0.33
"This study was conducted to determine the impact of knockout of selenium (Se)-dependent glutathione peroxidase-1 (GPX1-/-) or double knockout of GPX1 and copper, zinc (Cu,Zn)-super-oxide dismutase (SOD1) on cell death induced by acetaminophen (APAP) and its major toxic metabolite N-acetyl-P-benzoquinoneimine (NAPQI)."( Double null of selenium-glutathione peroxidase-1 and copper, zinc-superoxide dismutase enhances resistance of mouse primary hepatocytes to acetaminophen toxicity.
Lei, XG; Zhu, JH, 2006
)
0.33
"Acetaminophen (APAP) is safe at therapeutic levels but causes liver injury via N-acetyl-p-benzoquinone imine (NAPQI)-induced oxidative stress when overdose."( Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine.
Chan, EC; New, LS; Tan, SC, 2008
)
0.35
" For studies of toxic processes, 1H NMR spectroscopy of biofluids allows monitoring of endogenous metabolite profiles that alter characteristically in response to changes in physiological status."( A 1H NMR-based metabolomics approach for mechanistic insight into acetaminophen-induced hepatotoxicity.
Ando, Y; Fukuhara, K; Ohno, A; Okuda, H; Yamoto, T, 2011
)
0.37
" As fasting promotes SIRT3-mediated mitochondrial-protein deacetylation and acetaminophen metabolites bind to lysine residues, we investigated whether deacetylation predisposes mice to toxic metabolite-mediated disruption of mitochondrial proteins."( SIRT3-dependent deacetylation exacerbates acetaminophen hepatotoxicity.
Aponte, AM; Bourdi, M; Chen, Y; Gucek, M; Li, JH; Lombard, DB; Lu, Z; Pohl, LR; Sack, MN, 2011
)
0.37
" In the present study, therefore, we assessed the protective effect of Rg3 against N-acetyl-p-benzoquinone imine (NAPQI), a toxic metabolic intermediate of APAP."( The amelioration of N-acetyl-p-benzoquinone imine toxicity by ginsenoside Rg3: the role of Nrf2-mediated detoxification and Mrp1/Mrp3 transports.
Cho, MK; Gum, SI, 2013
)
0.39
" Thus, in spite of possessing cytoprotective attributes, Phl was generally toxic in our APAP models."( Phloretin cytoprotection and toxicity.
Geohagen, BC; Korsharskyy, B; LoPachin, RM; Nordstroem, L; Vydyanatha, A, 2018
)
0.48
"Acetaminophen-protein adducts are specific biomarkers of toxic acetaminophen (paracetamol) metabolite exposure."( Early acetaminophen-protein adducts predict hepatotoxicity following overdose (ATOM-5).
Buckley, NA; Chan, BSH; Chiew, AL; Isbister, GK; James, LP; McArdle, K; Pickering, JW, 2020
)
0.56
" This study examined a new biomarker of acetaminophen toxicity, which measures the amount of toxic metabolite exposure called acetaminophen-protein adduct."( Early acetaminophen-protein adducts predict hepatotoxicity following overdose (ATOM-5).
Buckley, NA; Chan, BSH; Chiew, AL; Isbister, GK; James, LP; McArdle, K; Pickering, JW, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" A pharmacokinetic study was conducted to quantitate changes in the formation clearance (Cl(f)) of NAPQI to assess in vivo the activation and inhibition of NAPQI formation by methylxanthines."( Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation.
Lee, CA; Lillibridge, JH; Nelson, SD; Slattery, JT, 1996
)
0.29
" The following study examined the pharmacokinetic profile and clinical associations of adducts in 53 adults with acute APAP overdose resulting in acute liver failure."( Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure.
Capparelli, E; Davern, TJ; Hinson, JA; James, LP; Lee, WM; Letzig, L; Roberts, DW; Simpson, PM, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
"Despite extensive clinical experience, no dose-response curve exists for acetaminophen toxicity in man."( A new predictor of toxicity following acetaminophen overdose based on pretreatment exposure.
Good, AM; Johnson, DW; Juurlink, DN; Sivilotti, ML; Yarema, MC, 2005
)
0.33
" Primary hepatocytes isolated from mice dosed with CFB are resistant to APAP toxicity."( Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen.
Aleksunes, LM; Kardas, MJ; Klaassen, CD; Manautou, JE; Moffit, JS; Slitt, AL, 2007
)
0.34
" In addition, the effectiveness and toxicity of many drugs vary depending on dosing time associated with 24-h rhythms of biochemical, physiological, and behavioral processes under the control of the circadian clock."( [Dosing time based on molecular mechanism of biological clock of hepatic drug metabolic enzyme].
Matsunaga, N, 2009
)
0.35
" Moreover, there is evidence that the maximum recommended dosage can induce hepatic cytolysis in some individuals."( Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease.
Fromenty, B; Michaut, A; Moreau, C; Robin, MA, 2014
)
0.4
" To illustrate the potential of this approach, the method was applied to quantify NAPQI-modified SA in plasma from rats dosed with acetaminophen."( Absolute quantitation of NAPQI-modified rat serum albumin by LC-MS/MS: monitoring acetaminophen covalent binding in vivo.
LeBlanc, A; Roy, R; Shiao, TC; Sleno, L, 2014
)
0.4
" Plasma samples were collected at 17 hr after dosing (during the manifestation of symptoms) and at one month (after recovery) and were subjected to LC-MS analysis of NAPQI-adducts."( LC-MS analyses of N-acetyl-p-benzoquinone imine-adducts of glutathione, cysteine, N-acetylcysteine, and albumin in a plasma sample: A case study from a patient with a rare acetaminophen-induced acute swelling rash.
Kubo, T; Lee, SH; Oe, T; Ozawa, M, 2019
)
0.51
" Distinct from known genetic, physiologic, and dosage associations dictating severity of hepatic injury, no known factors predict an absence of protein adduct formation at therapeutic APAP dosing."( Metabolomic Evaluation of N-Acetyl-p-Benzoquinone Imine Protein Adduct Formation with Therapeutic Acetaminophen Administration: Sex-based Physiologic Differences.
Arnold, CG; D'Alessandro, A; Dart, R; Dylla, L; Heard, K; Heard, S; Monte, AA; Reynolds, K; Rumack, B; Sonn, B, 2022
)
0.72
"This retrospective study interrogated serum samples collected for a prior study investigating fluctuations of alanine aminotransferase (ALT) over time with 4G daily APAP dosing for ≥ 16 days in subjects from Denver, Colorado."( Metabolomic Evaluation of N-Acetyl-p-Benzoquinone Imine Protein Adduct Formation with Therapeutic Acetaminophen Administration: Sex-based Physiologic Differences.
Arnold, CG; D'Alessandro, A; Dart, R; Dylla, L; Heard, K; Heard, S; Monte, AA; Reynolds, K; Rumack, B; Sonn, B, 2022
)
0.72
" Most importantly, the dose-response effects and time course of APAP accumulation and metabolism agree well with those of the liver injury development."( Metabolic Competency of Larval Zebrafish in Drug-Induced Liver Injury: A Case Study of Acetaminophen Poisoning.
Chen, Y; Ge, W; Song, W; Yan, R, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
quinone imineAn imine formed formally from a quinone by replacement of one or more atoms of quinonoid oxygen by =NH or =NR.
ketoimineA ketimine, R2C=NR' (R =/= H), in which R' is a keto (C=O) group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (9)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Xenobiotics450
CYP2E1 reactions019
Acetaminophen Metabolism Pathway3016
Ethanol metabolism resulting in production of ROS by CYP2E1117
Ethanol metabolism production of ROS by CYP2E1117

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Macrophage migration inhibitory factorHomo sapiens (human)IC50 (µMol)40.00000.03803.09109.8000AID1384608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cytokine productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of mature B cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
inflammatory responseMacrophage migration inhibitory factorHomo sapiens (human)
cell surface receptor signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of gene expressionMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of protein kinase A signalingMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of macrophage chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
carboxylic acid metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cell migrationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of B cell proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of tumor necrosis factor productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of myeloid cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
regulation of macrophage activationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
innate immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of fibroblast proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of protein metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of prostaglandin secretion involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of myeloid leukocyte cytokine production involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
protein homotrimerizationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of arachidonic acid secretionMacrophage migration inhibitory factorHomo sapiens (human)
cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protease bindingMacrophage migration inhibitory factorHomo sapiens (human)
dopachrome isomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine receptor bindingMacrophage migration inhibitory factorHomo sapiens (human)
protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
chemoattractant activityMacrophage migration inhibitory factorHomo sapiens (human)
identical protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
phenylpyruvate tautomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
extracellular regionMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
nucleoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytosolMacrophage migration inhibitory factorHomo sapiens (human)
plasma membraneMacrophage migration inhibitory factorHomo sapiens (human)
cell surfaceMacrophage migration inhibitory factorHomo sapiens (human)
vesicleMacrophage migration inhibitory factorHomo sapiens (human)
secretory granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular exosomeMacrophage migration inhibitory factorHomo sapiens (human)
ficolin-1-rich granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1346640Rat TRPA1 (Transient Receptor Potential channels)2010FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Dec, Volume: 24, Issue:12
Acetaminophen, via its reactive metabolite N-acetyl-p-benzo-quinoneimine and transient receptor potential ankyrin-1 stimulation, causes neurogenic inflammation in the airways and other tissues in rodents.
AID1346640Rat TRPA1 (Transient Receptor Potential channels)2011Nature communications, Nov-22, Volume: 2TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ(9)-tetrahydrocannabiorcol.
AID19325Half life was determined1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis, decomposition kinetics, and preliminary toxicological studies of pure N-acetyl-p-benzoquinone imine, a proposed toxic metabolite of acetaminophen.
AID25524Pseudo-first-order rate constant for the decomposition of compound at 25 degree C in presence of HCl at pH 2.001986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Detection of N-acetyl-p-benzoquinone imine produced during the hydrolysis of the model phenacetin metabolite N-(pivaloyloxy)phenacetin.
AID25521Pseudo-first-order rate constant for the decomposition of compound at 25 degree C in presence of HCl at pH 1.001986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Detection of N-acetyl-p-benzoquinone imine produced during the hydrolysis of the model phenacetin metabolite N-(pivaloyloxy)phenacetin.
AID232880Second order rate constant was determined1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis, decomposition kinetics, and preliminary toxicological studies of pure N-acetyl-p-benzoquinone imine, a proposed toxic metabolite of acetaminophen.
AID25525Pseudo-first-order rate constant for the decomposition of compound at 25 degree C in presence of HCl at pH 2.311986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Detection of N-acetyl-p-benzoquinone imine produced during the hydrolysis of the model phenacetin metabolite N-(pivaloyloxy)phenacetin.
AID212012Toxicity in mice 24 hr after ip administration1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis, decomposition kinetics, and preliminary toxicological studies of pure N-acetyl-p-benzoquinone imine, a proposed toxic metabolite of acetaminophen.
AID1384608Inhibition of recombinant human MIF tautomerase activity after 5 to 20 mins in presence of BSA by dopachrome tautomerase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.
AID25526Pseudo-first-order rate constant for the decomposition of compound at 25 degree C in presence of HCl at pH 2.621986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Detection of N-acetyl-p-benzoquinone imine produced during the hydrolysis of the model phenacetin metabolite N-(pivaloyloxy)phenacetin.
AID25522Pseudo-first-order rate constant for the decomposition of compound at 25 degree C in presence of HCl at pH 1.301986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Detection of N-acetyl-p-benzoquinone imine produced during the hydrolysis of the model phenacetin metabolite N-(pivaloyloxy)phenacetin.
AID25523Pseudo-first-order rate constant for the decomposition of compound at 25 degree C in presence of HCl at pH 1.591986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Detection of N-acetyl-p-benzoquinone imine produced during the hydrolysis of the model phenacetin metabolite N-(pivaloyloxy)phenacetin.
AID230781Rate constant was determined1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis, decomposition kinetics, and preliminary toxicological studies of pure N-acetyl-p-benzoquinone imine, a proposed toxic metabolite of acetaminophen.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (201)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (16.92)18.7374
1990's50 (24.88)18.2507
2000's38 (18.91)29.6817
2010's61 (30.35)24.3611
2020's18 (8.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.41 (24.57)
Research Supply Index5.36 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (2.42%)5.53%
Reviews11 (5.31%)6.00%
Case Studies2 (0.97%)4.05%
Observational3 (1.45%)0.25%
Other186 (89.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]